Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients

References

• Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17(S3):43–46.
   PubMedGoogle Scholar
• Al-Shahrani ZS, Al-Rawaji AI, Al-Madouj AN, et al. Cancer incidence report of Saudi Arabia. 2014;8:6–35.
   Google Scholar
• Mokdad AH, Jaber S, Aziz MI, et al. The state of health in the Arab world, 1990010: an analysis of the burden of diseases, injuries, and risk factors. Lancet. 2014;383:309–320.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–2128.
   PubMed Web of Science ®Google Scholar
• Al-Qahtani MS. Gut metastasis from breast carcinoma. Saudi Med J. 2007;28:1590–1592.
   PubMed Web of Science ®Google Scholar
• Ibrahim EM, Zeeneldin AA, Sadiq BB, et al. The present and the future of breast cancer burden in the Kingdom of Saudi Arabia. Med Oncol. 2008;25:387–393.
   PubMed Web of Science ®Google Scholar
• Al-Rawaji AI, Al-Shahrani ZS, Alzahrani W, et al. Kingdom of Saudi Arabia Saudi Health Council National Health Information Center Saudi Cancer Registry: Cancer Incidence Report Saudi Arabia 2015.September 2018.
   Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. on behalf of the Herceptin Adjuvant (hera) trial study team. Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. on behalf of the Breast Cancer International Research Group. Adjuvant trastuzumab in her2-positive breast cancer. N Engl J Med. 2011;365:1273–1283.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. on behalf of the Herceptin Adjuvant (hera) trial study team. 11 Years’ follow-up of trastuzumab after adjuvant chemotherapy in her2-positive early breast cancer: final analysis of the Herceptin Adjuvant (hera) trial. Lancet. 2017;389:1195–1205.
   PubMed Web of Science ®Google Scholar
• Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236–244.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31. Adjuvant chemotherapy with or without trastuzumab (H) in patients with HER2-positive breast cancer. Proc ASCO, Abstract. 2007; 512.
   Google Scholar
• Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. San Antonio Breast Cancer Symposium: Abstract. 2009; 80.
   Google Scholar
• Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27:6129–6134.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27:5685–5692.
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648.
   PubMed Web of Science ®Google Scholar
• Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–7819.
   PubMed Web of Science ®Google Scholar
• Wynne CJ, Ellis-Pegler RB, Waaka DS, et al. Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single use injection device in healthy males. Cancer Chemother Pharmacol. 2013;72:1079–1087.
   PubMed Web of Science ®Google Scholar
• Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C, et al. Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT Pharmacometrics Syst Pharmacol. 2014;3:e87.
   PubMedGoogle Scholar
• Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous antiCD52 monoclonal antibody alemtuzumab (Campath-1H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768–773.
   PubMed Web of Science ®Google Scholar
• Jackisch C, Dank M, Frasci G Additional safety results of HannaH: A Phase III randomised, open-label, international study of the subcutaneous formulation of trastuzumab (H) in HER2-positive early breast cancer patients. ESMO 2012 (abstract).
   Google Scholar
• Pivot X, Semiglazov V, Chen SC et al. Subcutaneous injection of trastuzumab – analysis of administration time and injection site reactions. ESMO 2012 (abstract).
   Google Scholar
• Leelahavarong P. Budget impact analysis. J Med Assoc Thai. 2014;97:S65–71.
   PubMedGoogle Scholar
• Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320–368.
   PubMed Web of Science ®Google Scholar
• OECD Data, purchasing power parities, https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm.
   Google Scholar
• World bank, https://data.worldbank.org/indicator/NY.GDP.PCAP.CN?locations=SA.
   Google Scholar
• Burcombe R, Chan S, Simcock R, et al. Subcutaneous Trastuzumab (Herceptin®): A UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Adv Breast Cancer Res. 2013;02:133–140.
   Google Scholar
• Lopez-Vivanco G, Salvador J, Diez R, et al. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clin Transl Oncol. 2017;19:1454–1461.
   PubMed Web of Science ®Google Scholar
• Romero M, Acero G, Huerfano L. Ana´ lisis De Minimizacio´n De Costos Del Uso De Trastuzumab Subcuta´neo Frente A Trastuzumab Intravenoso En El Tratamiento De Ca´ncer De Mama Temprano En Mujeres Con Her2 Positivo Para Venezuela. Value Heal. 2015;18:A823.
   Google Scholar
• Shinder GA, Paradis PE, Posman M, et al. Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada–a time and motion study. BMC Health Serv Res. 2012;12:370.
   PubMed Web of Science ®Google Scholar
• Papadmitriou K, Trinh XB, Altintas S, et al. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts Views Vis ObGyn. 2015;7:176–180.
   PubMed Web of Science ®Google Scholar
• De Cock E, Pivot X, Hauser N, et al., A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389–397.
   PubMed Web of Science ®Google Scholar
• Lieutenant V, Toulza E´, Pommier M, et al. Herceptin® (trastuzumab) par voie souscutane´e: une mini re´volution?E´ tude pharmaco-e´conomique. Bull Cancer. 2015;102:270–276.
   PubMedGoogle Scholar
• Hedayati E, Fracheboud L, Srikant V, et al., Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden. PLoS One. 2019;14(2):e0211783.
   Web of Science ®Google Scholar
• Pivot X, Gligorov J, Müller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open label randomised study. Lancet Oncol. 2013;14:962–970.
   PubMed Web of Science ®Google Scholar
• Chemotherapy unit, Oncology Centre, King Abdullah Medical City, Makkah, Saudi Arabia (2020).
   Google Scholar
• Central Intelligence Agency, The world Factbook, Saudi Arabia, https://www.cia.gov/library/publications/the-world-factbook/geos/sa.html
   Google Scholar